Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640521 | 0.83 | BMPR1B (0.48) | HRH3HTR2CCA1CA2HTR2A | |
| SCHEMBL1639551 | 0.80 | HRH3 (0.62) | HRH3CA1CA2 | |
| SCHEMBL1639547 | 0.77 | HRH3 (0.44) | HRH3CA1CA2 | |
| SCHEMBL1639543 | 0.77 | HRH3 (0.61) | HRH3 | |
| SCHEMBL1638987 | 0.77 | HRH3 (0.64) | HRH3CA1CA2 | |
| SCHEMBL1639003 | 0.76 | ESR1 (0.46) | HRH3CA1CA2 | |
| SCHEMBL1638986 | 0.76 | CA1 (0.65) | HTR2CCA1CA2HTR2B | |
| SCHEMBL2283767 | 0.72 | DRD3 (0.46) | HTR2CASIC3HTR2AHTR2B | |
| SCHEMBL1639562 | 0.72 | PDE3B (0.50) | HRH3HTR2CASIC3HTR2AHTR2B | |
| SCHEMBL18408249 | 0.70 | OPRM1 (0.55) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | claimed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | HRH3 1/4885HTR2C 56/4885CA1 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.